On the 12th, the U.S. Food and Drug Administration (FDA) formally approved a recombinant DNA (deoxyribonucleic acid) technology to produce the surgical suture is listed in the U.S., saying it was the first to rely on high-tech biotechnology developed absorbable suture.

Fosun suture  line called "TephaFLEX absorbable suture developed by the Massachusetts company. The doctor can make use of this suture line in patients with soft tissue connected together, so that the depth of a cut or surgical incision of soft tissue as soon as possible, the special material of the suture line in the suture after a period of time the human body to decompose.

R & D personnel using recombinant DNA technological transformation of bacteria, isolated from a particular substance as a raw material made of this absorbable polymer suture. Recombinant DNA technology can take advantage of the living organism to produce the chemicals are difficult to produce under standard industrial methods.

U.S. FDA Medical Devices and Radiological Health, Daniel Schultz said in a statement, this suture line is made using the most advanced DNA technology, this novel manufacturing technology in the field of medical device development wide range of applications.

According to the U.S. FDA medical device classification standards, the suture line was designated as the two medical devices, the degree of risk for middle. The FDA warned that patients used in the production process of the suture line cells or medium allergy, the doctor should prohibit their use of this suture line.